All-oral 12-week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Patients Infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study

被引：0

作者：

Nelson, David R. ^{[1
]}

Cooper, James N. ^{[2
]}

Lalezari, Jacob P. ^{[3
]}

Lawitz, Eric ^{[4
]}

Pockros, Paul J. ^{[5
]}

Gitlin, Norman ^{[6
]}

Freilich, Bradley ^{[7
]}

Younes, Ziad ^{[8
]}

Harlan, William ^{[9
]}

Ghalib, Reem H. ^{[10
]}

Oguchi, Godson I. ^{[11
]}

Thuluvath, Paul J. ^{[12
]}

Ortiz-Lasanta, Grisell ^{[13
]}

Rabinovitz, Mordechai ^{[14
]}

Bernstein, David ^{[15
]}

Bennett, Michael ^{[16
]}

Hawkins, Trevor ^{[17
]}

Ravendhran, Natarajan ^{[18
]}

Sheikh, Aasim M. ^{[19
]}

Varunok, Peter ^{[20
]}

Kowdley, Kris V. ^{[21
]}

Hennicken, Delphine ^{[22
]}

McPhee, Fiona ^{[22
]}

Rana, Khurram ^{[22
]}

Hughes, Eric A. ^{[22
]}

机构：

[1] Univ Florida, Gainesville, FL USA

[2] Inova Fairfax Hosp, Falls Church, VA USA

[3] Quest Clin Res, San Francisco, CA USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[5] Scripps Clin, La Jolla, CA 92037 USA

[6] Atlanta Gastroenterol Associates, Atlanta, GA USA

[7] Kansas City Res Inst, Kansas City, MO USA

[8] Gastro One, Germantown, TN USA

[9] Asheville Gastroenterol Associates, Asheville, NC USA

[10] Texas Clin Res Inst, Arlington, TX USA

[11] Midland Florida Clin Res Ctr, Deland, FL USA

[12] Mercy Med Ctr, Baltimore, MD USA

[13] Fdn Invest Diego, Santurce, PR USA

[14] Univ Pittsburgh, Pittsburgh, PA USA

[15] Hofstra North Shore Long Isl Jewish Sch Med, Manhasset, NY USA

[16] Med Associates Res Grp, San Diego, CA USA

[17] Southwest CARE Ctr, Santa Fe, NM USA

[18] Digest Dis Associates, Baltimore, MD USA

[19] Gastrointestinal Specialists Georgia, Marietta, GA USA

[20] Premier Med Grp Husdon Valley, Poughkeepsie, NY USA

[21] Swedish Med Ctr, Seattle, WA USA

[22] Bristol Myers Squibb Res & Dev, Princeton, NJ USA

来源：

HEPATOLOGY | 2014年 / 60卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LB-3

引用

页码：1268A / 1269A

页数：2

共 50 条

[21] PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR plus RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG plus RIBAVIRIN IN TREATMENT-NAIVE GT2/3 HCV-INFECTED PATIENTS (FISSION)
Gane, E.
Lawitz, E.
Rodriguez-Torres, M.
Gordon, S.
Dvory-Sobol, H.
Arterburn, S.
McNally, J.
Brainard, D. M.
Symonds, W. T.
McHutchison, J. G.
Sheikh, A.
Mangia, A.
JOURNAL OF HEPATOLOGY, 2013, 58 : S3 - S3
[22] All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1)
Sulkowski, Mark S.
Rodriguez-Torres, Maribel
Lalezari, Jacob P.
Fessel, W. Jeffrey
Mounzer, Karam
Shuhart, Margaret C.
Luetkemeyer, Anne
Asmuth, David M.
Gaggar, Anuj
Symonds, William T.
McHutchison, John G.
Naggie, Susanna
Dieterich, Douglas T.
HEPATOLOGY, 2013, 58 : 313A - 314A
[23] The European Commission has an Extension of the Treatment Recommendations for Daclatasvir (Daklinza (R)) for the 12-week Treatment of non cirrhotic HCV- Patients with Genotype 3
Viragh, Eszter
VISZERALMEDIZIN, 2015, 31 (05):
[24] The efficacy of sofosbuvir/velpatasvir/ribavirin in cirrhotic, genotype 3a HCV patients, previously failures to sofosbuvir/daclatasvir/ribavirin combination
Dimitroulopoulos, D.
Karatapanis, S.
Kypreos, D.
Malahias, A.
Tsamakidis, K.
Xinopoulos, D.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 71 - 71
[25] All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Study
Chayama, Kazuaki
Suzuki, Fumitaka
Suzuki, Yoshiyuki
Toyota, Joji
Karino, Yoshiyasu
Kawakami, Yoshiiku
Fujiyama, Shigetoshi
Ito, Takayoshi
Itoh, Yoshito
Tamura, Etsuko
Ueki, Tomoko
Ishikawa, Hiroki
Linaberry, Misti
Hughes, Eric A.
Kumada, Hiromitsu
HEPATOLOGY, 2014, 60 : 1135A - 1135A
[26] Combination Therapy of Daclatasvir (Daklinza®) with Sofosbuvir and Ribavirin in HCV-Patients with Genotype 3 and advanced Fibrosis or Cirrhosis
Viragh, Eszter
VISCERAL MEDICINE, 2016, 32 (01) : 64 - 64
[27] Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study
Mangia, Alessandra
Roberts, Stuart K.
Pianko, Stephen
Thompson, Alex J.
Cooper, Curtis
Conway, Brian
Bourliere, Marc
Asselah, Tarik
Berg, Thomas
Zeuzem, Stefan
Rosenberg, William M.
Agarwal, Kosh
Gane, Edward J.
Stedman, Catherine A.
Mazzotta, Francesco
Tran, Tram T.
Gordon, Stuart C.
Svarovskaia, Evguenia S.
Han, Lingling
McNally, John
Osinusi, Anu
Brainard, Diana M.
McHutchison, John G.
Afdhal, Nezam H.
Foster, Graham R.
HEPATOLOGY, 2015, 62 : 338A - 339A
[28] Impact of Daclatasvir-Sofosbuvir Combination Treatment on Medical Events and Costs in Patients Infected with Genotype 3 Hepatitis C Virus
Gorsh, Boris
Sill, Bruce E.
Hede, Shalini
Thibault, Catherine St-Laurent
Moorjaney, Divya
Ganz, Michael
Kalsekar, Anupama
Yuan, Yong
HEPATOLOGY, 2015, 62 : 920A - 921A
[29] All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 Ion-2 Study
Kwo, Paul Y.
Reddy, K. Rajender
Pockros, Paul J.
Di Bisceglie, Adrian M.
Arora, Sanjeev
Yang, Jenny C.
Dvory-Sobol, Hadas
Zhu, Yanni
Pang, Phil
Symonds, William T.
McHutchison, John G.
Sulkowski, Mark
Afdhal, Nezam H.
GASTROENTEROLOGY, 2014, 146 (05) : S904 - S904
[30] ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY
Afdhal, N.
Reddy, R. K.
Pockros, P.
Di Bisceglie, A. M.
Arora, S.
Yang, J. C.
Dvory-Sobol, H.
Zhu, Y.
Pang, P. S.
Symonds, W. T.
McHutchison, J. G.
Sulkowski, M. S.
Kwo, P.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S45 - S45

← 1 2 3 4 5 →